To investigate whether the combination treatment of CpG and RT improves tumor growth delay compared with single therapy with CpG alone or RT alone in a primary tumor model, we induced STS with a high mutational load in 129/SvJae mice by injecting an adenovirus-expressing CRISPR-Cas9, a single-guide RNA (sgRNA) targeting Trp53 (sgp53) (10), and the carcinogen 3-methylcholanthrene (MCA) into the gastrocnemius muscle (11) (Figure 1A). Here, TP53 is linked to telomere syndrome.